Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Juni 2015 08:00 ET | Quelle: Cellerant Therapeutics

Cellerant Appoints Rodney Young as Chief Financial Officer

SAN CARLOS, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...
17. März 2015 08:00 ET | Quelle: Cellerant Therapeutics

Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients

SAN CARLOS, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...
05. Dezember 2014 13:07 ET | Quelle: Cellerant Therapeutics

Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients With Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting

SAN CARLOS, Calif., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., announced that data from the Phase 1 clinical trial for CLT-008, a first-in-class, allogeneic, cell-based therapy for...
11. September 2014 08:00 ET | Quelle: Cellerant Therapeutics

Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008

Total Contract With Biomedical Advanced Research and Development Authority Valued at $163.8MM Additional Funding to Support Planned Phase 2 Trial With CLT-008 in AML SAN CARLOS, Calif., Sept....